Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

One hundred ninety patients who had advanced active Hodgkin's disease, lymphosarcoma, or reticulum cell sarcoma were treated with a combination of cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) given in a cyclical fashion every month. Complete remission was produced in 91 of 138 (66%) patients with Hodgkin's disease and in 39 of 52 (75%) patients with non-Hodgkin's lymphoma (lymphosarcoma and reticulum cell sarcoma). The response rate was higher in patients who completed six cycles of therapy compared to those who completed only three to five cycles: 77% vs. 45%, respectively, in Hodgkin's disease, and 85% vs. 46%, respectively, in non-Hodgkin's lymphoma. The median duration of remission was longer for Hodgkin's disease patients who completed six cycles (30 months vs. 10 months). The median duration of complete remission of non-Hodgkin's lymphoma was 14 months. The response to treatment correlated positively with survival. The median survival time start of COPP treatment for patients with Hodgkin's disease was 7 months for nonresponders, 14 months for those who attained partial remission, and more than 48 months for those who attained complete remission. For patients with non-Hodgkin's lymphoma, the median survival time from start of COPP treatment was 24 months for nonresponders and those who had partial remission, and more than 32 months for those who attained complete remission. Of complete remission responders with Hodgkin's disease, 70% are still alive 84 months after diagnosis, and 63% of the patients witn non-Hodgkin's lymphoma are still alive 48 months after diagnosis.
 ...
PMID:Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients. 110 Feb 20

The clinical and pathological features of 64 children with non-Hodgkin's malignant lymphoma seen between April 1962 and June 1973 are described. Forty-one children had diffuse, undifferentiated, non-Burkitt lymphoma (lymphoblastic lymphoma). They tended to be boys under 10 years of age and their median survival was 1 year. Almost one-third are surviving for 1-11 years, most in initial complete remission. Nineteen children had diffuse, poorly differentiated, histiocytic lymphoma. They tended to be boys more than 10 years of age, their median survival was only 6 months, and only the 3 patients with Stage I peripheral node tumour survived. Two children had nodular, lymphocytic, poorly differentiated lymphoma and 2 had lymphoma resembling the Burkitt type. From our clinical and pathological observations, we conclude that non-Hodgkin's malignant lymphomata in children cannot be separated from the acute lymphocytic, histiocytic and unclassified leukaemias by cytological or histological methods. What is called diffuse, undifferentiated, non-Burkitt type, or lymphoblastic lymphoma is actually acute lymphocytic leukaemia without apparent invasion of marrow and peripheral blood by neoplastic lymphocytes at time of diagnosis. What is termed diffuse, histiocytic lymphoma is acute histiocytic leukaemia without apparent infiltration of marrow and peripheral blood at initial presentation. One could say just as well that acute lymphocytic leukaemia is Stage IV lymphoblastic lymphoma and that acute histiocytic leukaemia is Stage IV histiocytic lymphoma. Further classification of lymphocytic and histiocytic cancers by newer functional, chemical and morphological methods should include both what is called lymphocytic or histiocytic leukaemia and what is called non-Hodgkin's lymphoma as one group of diseases, susceptible to subclassification by the new methods. We recommend that Stage I lymphocytic and histiocytic cancers be treated with local irradiation. Patients with Stages II-IV tumours should receive anti-leukaemic forms of therapy including prolonged multiple agent chemotherapy and preventive central nervous system irradiation. Staging laparotomy should be considered in patients with Stage I tumour in low cervical, axillary and inguinal nodes.
 ...
PMID:Non-Hodgkin's lymphoma in children. 110 24

The analysis of the results of CVP and MOPP chemotherapy in 80 patients with advanced stages of non-Hodgkin's lymphoma shows that 36 achieved a complete remission. Twenty-five percent of all patients remain free of disease for periods ranging from 4 months to over 7 years, with a projected median duration of complete remissions of 3 1/2 years. Well differentiated and nodular histology were positive determinants for survival, confirming the overall clinical validity of the Rappaport classification system for the non-Hodgkin's lymphomata. However, it has been demonstrated that it is possible to achieve a complete remission using combination chemotherapy even in the most clinically aggressive histological subgroups, and that these responses can be correlated with an extended survival. An analysis of patterns of relapse from complete remission in patients with non-Hodgkin's lymphoma treated with combination chemotherapy has demonstrated differences between histological subgroups. Patients with diffuse histiocytic lymphoma who achieved a complete remission after 6 months of treatment without maintenance have remained disease-free, whereas those with nodular poorly differentiated lymphocytic and diffuse well differentiated lymphocytic lymphomata demonstrate a pattern of continuous late recurrence. The initial sites of relapse from complete remission in lymphocytic lymphoma were lymph nodes and bone marrow which were involved before treatment.
 ...
PMID:Results of combination chemotherapy of non-Hodgkin's lymphoma. 110 32

A retrospective study of 460 non-Hodgkin's lymphoma patients seen in 1962-64 (185) and 1967-69 (275) revealed a marked improvement in the survival of patients treated during the later interval. The increased survival was not due to differences in the age or sex distribution of patients, the proportions with systemic symptoms or extranodal presentations. The improvement was due partially to a disproportionate increase in the number of patients with well- and intermediately differentiated nodular lymphocytic lymphomata in 1967-69. When these patients were removed, the proportions of patients with "good" and "poor" pathology were comparable for the two intervals, and a markedly improved survival was still evident for the 1967-69 group. An improvement in the proportion of patients achieving a complete remission occurred only in patients who received some form of chemotherapy. Relapses occurred in 44.6% of patients with Stage I and II disease treated with radiotherapy alone. The results of this study indicate that we must re-evaluate carefully the indications for radiotherapy in the treatment of the non-Hodgkin's lymphomata. The addition of chemotherapy appears to be a promising method for increasing the proportion of patients who will achieve a long complete remission.
 ...
PMID:The influence of chemotherapy on the management of non-Hodgkin's lymphomata at the Princess Margaret Hospital. A comparison of the results from 1962-64 with 1967-69. 110 34

Much of the approach to evaluation and management of the non-Hodgkin's lymphomas has been modeled after Hodgkin's disease. However, as the name implies, they are quite different. The non-Hodgkin's lymphomas are a group of diseases and syndromes. These many different presentations, syndromes, and possibly different diseases must be distinguished and separated in order to evaluate results. Advances in pathologic classification attempting to relate the disease to physiological activities of lymphocytes are being made, but a simple, clinically relevant scheme is not available at present. We recognize large differences in nodular vs. diffuse histologic patterns. Non-Hodgkin's lymphoma is only infrequently restricted to a single anatomical area, but when it is, radiation therapy can result in a significant proportion of cures. More widespread disease requires systemic therapy. Most encouraging results are found with whole-body radiation used as a systemic agent with the use of multidrug combination chemotherapy. Perhaps whole-body radiation will be most useful when combined with combination chemotherapy as systemic therapy for some groups of non-Hodgkin's lymphoma.
 ...
PMID:The treatment of non-Hodgkin's lymphoma. 115 38

A history of prolonged diphenylhydantoin (Dilantin) therapy was reported by 8 of 516 patients (1.6%) with Hodgkin's disease or non-Hodgkin's lymphoma, as compared with 3 of 516 patients (0.6%) with other cancers, and 2 of 516 (0.4%) tumor-free individuals. The findings, together with other published data, suggest a small excess risk of malignant lymphomas in patients receiving long-term treatment with this drug. The immunosuppressive effects of chronic diphenylhydantoin therapy may be involved in the pathogenesis of these neoplasms.
 ...
PMID:Malignant lymphoma after diphenylhydantoin (dilantin) therapy. 117 33

The non-Hodgkin's lymphomata are characteristically near diploid with occasional examples having higher chromosome numbers. In contrast, about half the cases of Hodgkin's disease have chromosome numbers in the triploid range. Karyotypes in cases of Hodgkin's disease appear to be more deranged than those found in other lymphomata, even when the cells are in the diploid range. If karyotypically normal cells in the tumours represent some degree of host reaction, then this is most marked in Hodgkin's disease. Long arm deletions of chromosome 18 were identified in cells from 7/31 cases of non-Hodgkin's lymphoma; 5 were follicular and 2 contained both follicular and diffuse areas. The cases showing this deletion had a relatively good prognosis.
 ...
PMID:A comparison of cytogenetics and histopathology in the malignant lymphomata. 118 67

Twenty patients with non-Hodgkin's lymphoma (NHL) were investigated by diagnostic laparotomy. These patients were seen over a 3 1/2 year period during which a total of 78 patients with NHL were seen. Laparotomy was considered unsuitable in 58 patients, either because widespread disease was easily demonstrated by simpler means or because of their poor general medical condition. Laparotomy revealed more extensive disease in 14 patients. Although laparotomy is proving to be a worthwhile investigative procedure, it is less likely to be useful as a routine investigation than is the case with Hodgkin's disease. Widespread involvement of mesenteric lymph nodes is common and among the 10 patients with a poor histological grade of tumour, 2 with negative laparotomy findings developed disease in the abdomen within 3 months of operation.
 ...
PMID:Diagnostic laparotomy in non-Hodgkin's lymphoma. 118 72

The pattern of Hodgkin's disease has changed significantly with the use of radical radiotherapy (total nodal irradiation) and chemotherapy, and with the general adoption of the histological classification of LUKES and the Ann Arbor modification of Rye staging system. Histological classification of non-Hodgkin's lymphoma is far from satisfactory, a fact which renders evaluation of the optimum treatment difficult. Spread is usually hematogenic. Bone marrow and mesenteric nodes are involved in 60% of cases, and therefore total nodal irradiation is ineffective in eradicating the disease. Chemotherapy is the treatment of choice except in some stages IE and IIE when, after careful pretherapy evaluation, local radiotherapy may be sufficient. In generalized lymphomas the role of total body irradiation is still under study.
 ...
PMID:[Do we have to treat non-Hodgkin's lymphomas the same as Hodgkin's disease?]. 121 6

Enhanced tolerance to combination chemotherapy has been cited as an ancillary benefit of staging laparotomy and splenectomy in Hodgkin's disease. Seventeen patients with Hodgkin's disease and 15 with non-Hodgkin's lymphoma were subjected to nontherapeutic splenectomy as part of the staging procedure prior to their initial treatment with MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) or CVP (cyclophosphamide, vincristine, and prednisone) chemotherapy, respectively. Matched control patients of comparable age, pathologically proven stage, and presence or absence of bone marrow lymphoma and previous radiotherapy were selected. Although leukocyte (in non-Hodgkin's patients) and platelet counts (in both groups) were significantly higher in the patients with splenectomy during most of the first six cycles of therapy, there was no difference in the number of cycles during which a leukocyte count below 1000 (or below 2000 in Hodgkin's disease) or platelet count below 50,000 was recorded in the splenectomized and control patients. The total dose of all drugs actually delivered, time required to complete six cycles of treatment, and the portion of patients entering complete remission were not significantly different in the two groups. We have found no evidence that splenectomy per se, in lymphoma patients without findings of hypersplenism, improves the ability to administer planned amounts of drugs during initial combination chemotherapy.
 ...
PMID:Effect of splenectomy on tolerance to combination chemotherapy in patients with lymphoma. 124 20


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>